Encyclopedia of contested claims
Aspirin can lower the chance of some first cardiovascular events in selected adults, but it also increases bleeding risk. For many healthy adults, especially older adults or people at low cardiovascular risk, the balance of benefit and harm is uncertain or unfavorable.
9 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its full review of this claim. This draft summarizes the main issues that reviewers are likely to examine, including randomized trial evidence, guideline recommendations, differences by age and cardiovascular risk, and the tradeoff between fewer first heart attacks and more bleeding events.
Aspirin can lower the chance of some first cardiovascular events in selected adults, but it also increases bleeding risk. For many healthy adults, especially older adults or people at low cardiovascular risk, the balance of benefit and harm is uncertain or unfavorable.
The claim asks whether aspirin prevents first heart attacks in healthy adults. This is a question about primary prevention, meaning aspirin use before a person has had a heart attack, stroke, coronary stent, or other established cardiovascular disease.
Aspirin reduces blood clotting by inhibiting platelet activity. Because many heart attacks involve clot formation in narrowed coronary arteries, aspirin has a plausible mechanism for reducing some first heart attacks. However, the same anti-clotting effect can also raise the risk of gastrointestinal bleeding and bleeding in or around the brain.
The word "healthy" matters. A person with diabetes, high blood pressure, high cholesterol, smoking history, chronic kidney disease, or a high calculated 10-year cardiovascular risk may not fit the everyday meaning of healthy, even if they have not had a prior heart attack. Modern recommendations usually separate adults by age, bleeding risk, and estimated cardiovascular risk rather than treating all healthy adults as one group.
Large randomized trials and meta-analyses generally find that aspirin used for primary prevention can reduce nonfatal myocardial infarction or composite cardiovascular events by a modest amount in some groups. The absolute benefit is usually small for adults with low baseline cardiovascular risk, because their chance of a first heart attack is already relatively low.
The same evidence consistently shows an increased risk of major bleeding, especially gastrointestinal bleeding and, less commonly, intracranial bleeding. This bleeding risk rises with age and with factors such as prior ulcers, use of blood thinners or nonsteroidal anti-inflammatory drugs, uncontrolled hypertension, or other medical conditions.
Guidelines have shifted over time. The U.S. Preventive Services Task Force recommends that the decision to start low-dose aspirin for primary prevention in adults aged 40 to 59 with a 10-year cardiovascular disease risk of at least 10% should be individualized, and recommends against initiating aspirin for primary prevention in adults 60 or older. Cardiology guidelines similarly emphasize selective use rather than routine use in healthy adults.
This makes the overall answer mixed: aspirin may prevent some first heart attacks in selected higher-risk adults, but routine use by healthy adults is not generally supported because bleeding harms can offset cardiovascular benefits.
Uncertainty remains for individuals near decision thresholds, such as adults in middle age with elevated cardiovascular risk but low bleeding risk. The expected benefit depends heavily on baseline risk, which can be estimated but not predicted perfectly for any one person.
The evidence also continues to evolve as background prevention improves. Wider statin use, better blood pressure treatment, lower smoking rates in some populations, and improved diabetes management may reduce the added benefit of aspirin compared with earlier eras.
There may also be subgroup differences by sex, age, diabetes status, coronary artery calcium score, and genetic or bleeding-risk factors. These questions are important because aspirin’s average effect in a large population may not describe the best choice for a particular patient.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 78% | No · 84% | No · 72% | No · 90% |
| Mistral Medium 3.5 | No · 78% | No · 84% | No · 72% | No · 90% |
| Llama 4 Maverick | No · 78% | No · 84% | No · 72% | No · 90% |
| OpenAI GPT-5.4 | No · 78% | No · 84% | No · 72% | No · 90% |
| Gemini 3.1 Pro | No · 78% | No · 84% | No · 72% | No · 90% |
| Claude Opus 4.7 | No · 78% | No · 84% | No · 72% | No · 90% |
| DeepSeek V4 Pro | No · 78% | No · 84% | No · 72% | No · 90% |
| GLM 5.1 | No · 78% | No · 84% | No · 72% | No · 90% |
| Qwen 3.7 Max | No · 78% | No · 84% | No · 72% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
Aspirin at low doses reduces first nonfatal heart attacks by about 10-15% relative risk in adults without known cardiovascular disease, per meta-analyses underlying the cited ACC/AHA and USPSTF reviews, yet it...
Aspirin has a modest effect in reducing the risk of a first nonfatal heart attack in some healthy adults, particularly those at higher cardiovascular risk, but this benefit is offset by an increased risk of ble...
Aspirin may prevent first heart attacks in some healthy adults, but its use is not universally recommended due to the associated bleeding risk. The confidence in this assessment is moderate. Key evidence suppor...
Mostly no. Aspirin does not broadly “prevent first heart attacks in healthy adults” in a way that justifies routine use. The best current evidence shows a small reduction in some first cardiovascular events, in...
Aspirin is not recommended for routine use to prevent first heart attacks in healthy adults. While low-dose aspirin can marginally reduce the risk of a first nonfatal heart attack, the concurrent increase in th...
Aspirin can modestly reduce the risk of a first nonfatal myocardial infarction in some adults without established cardiovascular disease, but it does not reliably prevent first heart attacks in "healthy adults"...
Aspirin does not prevent first heart attacks in healthy adults in a way that provides clear net benefit. While low-dose aspirin modestly reduces the risk of a first nonfatal myocardial infarction in some indivi...
Aspirin can reduce the risk of a first nonfatal heart attack in some adults without known cardiovascular disease, but it should not be routinely taken by healthy adults for primary prevention due to increased b...
Aspirin reduces the risk of a first nonfatal heart attack in some adults without known cardiovascular disease, but healthy adults should not routinely take it for primary prevention because the cardiovascular b...
